Older women who take hormone pills that combine estrogen and testosterone more than double their risk of breast cancer, according to a study of more than 70,000 nurses.
“This type of hormone therapy may help with mood, libido and bone mineral density, but the possible risk of breast cancer may outweigh these benefits,” said study co-author Rulla Tamimi of Harvard Medical School.
The findings, published in Monday’s Archives of Internal Medicine, add to the evidence that certain types of hormone supplements, such as estrogen-progestin pills, increase women’s risk of breast cancer, strokes and heart attacks. Earlier research also found a greater breast cancer risk in women with higher natural levels of testosterone.
The overall risk of breast cancer among the participants in the latest study was small, with 17 cases of the disease among the 500 or so women who took the estrogen-testosterone combination.
Women’s natural levels of estrogen and testosterone decline with menopause.
Only about 2 percent of women taking hormones in the study in 2000 used a form that included testosterone
Only about 2 percent of women taking hormones in the study in 2000 used a form that included testosterone. But usage climbed during the 24 years of the study as evidence appeared linking the hormone combination to better bone density, improved mood and greater sexual enjoyment.
Estrogen-testosterone pills are sold under the brand names Estratest and Estratest H.S. by Solvay Pharmaceuticals of Marietta, Ga. Those brand names appear on a Washington-based advocacy group’s “Worst Pills” list because of breast cancer risk.
“We strongly urge women not to use this product or similar products from compounding pharmacists,” said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group, which produces the Worst Pills list.
The Food and Drug Administration has asked Solvay for evidence the drug eases hot flashes in menopausal women, as the label claims. The company has requested a hearing on the matter.
The drug was approved 30 years ago
The drug was approved 30 years ago, before such evidence was required.
The new study used data from the long-running Nurses’ Health Study. The women who took estrogen and testosterone after menopause had a 2 1/2 times higher risk of developing breast cancer than women who never took hormones. Most of the women taking the combination used Estratest.
“The company has not yet had the opportunity to review the details of the study or the content of the article,” said Solvay spokesman Gabrielle Braswell.
The researchers took into account other breast cancer risk factors, such as family history, weight and age at menopause and still found an increased risk associated with estrogen-testosterone pills.